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Abstract
Aims/hypothesis Adults with type 2 diabetes are at high risk of developing cardiovascular disease (CVD). Evidence of the
impact of weight loss on incidence of CVD events among adults with diabetes is sparse and conflicting. We assessed weight
change in the year following diabetes diagnosis and estimated associations with 10 year incidence of CVD events and all-cause
mortality.
Methods In a cohort analysis among 725 adults with screen-detected diabetes enrolled in the Anglo–Danish–Dutch Study of
Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION)–Cambridge trial, we estimated HRs
for weight change in the year following diabetes diagnosis and 10 year incidence of CVD (n = 99) and all-cause mortality (n = 95)
using Cox proportional hazards regression. We used linear regression to estimate associations between weight loss and CVD risk
factors. Models were adjusted for age, sex, baseline BMI, smoking, occupational socioeconomic status, cardio-protective
medication use and treatment group.
Results Loss of ≥5% body weight in the year following diabetes diagnosis was associated with improvements in HbA1c and
blood lipids and a lower hazard of CVD at 10 years compared with maintaining weight (HR 0.52 [95% CI 0.32, 0.86]). The
associations between weight gain vs weight maintenance and CVD (HR 0.41 [95% CI 0.15, 1.11]) and mortality (HR 1.63 [95%
CI 0.83, 3.19]) were less clear.
Conclusions/interpretation Among adults with screen-detected diabetes, loss of ≥5% bodyweight during the year after diagnosis
was associated with a lower hazard of CVD events compared with maintaining weight. These results support the hypothesis that
moderate weight loss may yield substantial long-term CVD reduction, and may be an achievable target outside of specialist-led
behavioural treatment programmes.
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Introduction
Adults with type 2 diabetes are at high risk of developing car-
diovascular disease (CVD) [1]. CVD is the most common and
most costly diabetes complication, accounting for nearly half of
total treatment costs globally [2, 3].Weight loss has been shown
to improve CVD risk factors such as HbA1c, blood lipids and
BP among people with type 2 diabetes [4–6] and may also lead
to diabetes remission [7]. However, while improvements in
these risk factors have been demonstrated in short-term studies
[4, 8], few studies have assessed CVD events.
The existing literature on change in weight and CVD among
adults with diabetes is limited, and studies have shown incon-
clusive and inconsistent associations of weight loss and CVD
risk [9–12]. In the Action for Health in Diabetes (Look
AHEAD) randomised trial among obese adults with clinically
diagnosed diabetes of 7 years’ duration, the behavioural inter-
vention assessed in the trial did not appear to reduce CVD
incidence [6], although participants who lost at least 10% of
their body weight in 1 year had a 21% lower 10 year risk of
CVD compared with those with stable weight or weight gain
[10]. However, weight loss observed among trial participants
may not be representative of what would be achievable in the
general population in the absence of an intensive intervention
programme. Furthermore, as population-based screening for
type 2 diabetes has become increasingly common,
understanding the impact of weight changes early in the diabe-
tes disease trajectory is needed to inform clinical practice at the
time of diagnosis, when patients may be more receptive to care
[13].
Considering the challenge of controlling CVD risk factors
among individuals with established diabetes and the risks as-
sociated with intensification of therapy [14, 15], the year fol-
lowing diagnosis may be a critical time to establish healthy
behaviours that lead to long-term comorbidity reduction.
Weight loss during this period may result in a legacy effect,
whereby improvements in risk factors early in the course of
the disease yield long-term CVD benefits. In the UK
Prospective Diabetes Study (UKPDS), intensive glucose con-
trol following diabetes diagnosis was associated with lower
risk of CVD 10 years after the trial, even though differences in
glucose control were not maintained after the end of the trial
[16]. The Diabetes Care in General Practice trial of people
with a new diagnosis of diabetes showed no association be-
tween 13 year CVD incidence and weight loss achieved
through a 6 year intensive intervention [17]. However, this
study had a relatively small sample size (N = 444) and partic-
ipants had to survive until the end of the 6 year intervention
period in order to be followed up for CVD, which might have
resulted in a healthier study population relative to the target
population [18]. The Retrospective Study of Cardiovascular
Events Related to the Use of Glucose-Lowering Drug
Treatment in Primary Care (ROSE) cohort study of individ-
uals in Swedish primary care (N = 8486) showed that weight
loss in the 18 months following diabetes diagnosis had no
protective association with CVD events during a median
follow-up time of 4.6 years; however, weight gain was asso-
ciated with 63% higher hazard of CVD [12]. Given the mixed
results of studies of weight loss and CVD and the limited
generalisability of results from intensive weight loss trials,
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additional population-based research is needed to characterise
the impacts of weight loss after diabetes diagnosis on long-
term CVD incidence.
Using data from a population-based study of screening for
type 2 diabetes, the Anglo–Danish–Dutch Study of Intensive
Treatment in People with Screen-Detected Diabetes in Primary
Care (ADDITION)–Cambridge [19], we assessed the associa-
tion of weight change in the year following diabetes diagnosis
and 10 year CVD and mortality incidence, and the impact of
weight change on CVD risk factors (BP, blood lipid and HbA1c
levels) at 1 year and 5 years following diagnosis.
Methods
ADDITION–Cambridge (ISRCTN86769081) is a pragmatic
cluster-randomised trial comparing multifactorial intervention
vs routine care among people with screen-detected diabetes
from 49 general practices (GPs) in eastern England [19]. The
present study is an observational analysis of the trial cohort. A
validated risk score was used to identify eligible individuals
aged 40–69 years who were at high risk of diabetes, using the
electronic records of participating GPs [20]. From 2002 to
2006, 33,539 high-risk individuals were invited to attend a
stepwise screening programme; 24,654 (74%) took part [21].
During screening, 867 participants were diagnosed with type
2 diabetes using the 1999WHO criteria [22] and all consented
to enrol in the study. The GPs were cluster-randomised to
intensive treatment (n = 26) or routine care (n = 23). In the
routine care group, GPs were advised to follow current UK
guidelines for diabetes management [23–25]. Intensive treat-
ment included more frequent consultations, provision of edu-
cational materials and GP-based academic-detailing sessions
encouraging earlier use of medication to improve control of
risk factors. The intervention did not include behavioural
treatment. Written informed consent was obtained from all
participants and ethics approval was obtained from the re-
search ethics committees in Cambridge (ref. 01/063),
Huntingdonshire (ref. 00/609), Peterborough and Fenland
(ref. P01/95), West Essex (ref. 1511–0103), North and Mid
Essex (ref. MH395 MREC02/5/54), West Suffolk (ref. 03/
002), and Hertfordshire and Bedfordshire (ref. EC03623)
Local Research Ethics Committees and the Eastern Multi-
Centre Research Ethics Committee (ref. 02/5/54).
Measurements
Anthropometric, biochemical, clinical and questionnaire-
based measures were taken at the time of diabetes diagnosis
(baseline) and after 1 and 5 years [19]. Sociodemographic
information (age, sex, occupation and ethnicity), smoking sta-
tus and prescribed pharmacological treatment were self-
reported via standardised questionnaires. Information on
pharmacological treatment at 5 years was supplemented using
GP electronic records. Socioeconomic status (SES) was de-
fined according to the Registrar General’s occupation-based
classification: ‘professional, managerial and technical’,
‘skilled-manual and non-manual’ and ‘partly skilled or un-
skilled’ [26]. Clinical and anthropometric measures were per-
formed by trained staff, according to standard procedures [19].
CVD and mortality outcomes
The outcomes of interest were CVD events and all-cause mor-
tality. The composite CVD outcome included cardiovascular
mortality, non-fatal myocardial infarction, non-fatal stroke,
non-traumatic amputation, and revascularisation (both inva-
sive cardiovascular and peripheral vascular procedures).
Incidence of CVD events and mortality was ascertained from
the date of diabetes diagnosis until 31 December 2014.
Participants were flagged using National Health Service
(NHS) patient numbers for mortality surveillance by the
Office for National Statistics. Possible CVD outcomes were
identified via searches of GP notes, hospital discharge sum-
maries, hospital notes, electrocardiograms, laboratory results,
death certificates, autopsies and the Myocardial Ischaemia
National Audit Project (MINAP) [27]. All events were inde-
pendently adjudicated using standardised case report forms.
Statistical analysis
Of the 867 adults enrolled in the ADDITION–Cambridge
study, we were unable to include 137 for whom we could
not determine weight change, as they were missing data on
weight measurements at baseline or 1 year. We also excluded
individuals who had a CVD event in the first year in the study
(n = 5), as this was when weight change was measured.
Therefore, this study included 725 participants with 99 CVD
events. Mortality analyses also excluded deaths occurring
within 1 year after weight change was assessed (n = 2), as
weight loss might have been due to underlying disease; this
left a total of 95 all-cause mortalities during the study period.
We assessed predictors of missing weight information by
comparing distributions of factors measured at baseline be-
tween individuals whowere and who were not missing weight
measurements.
The proportion of weight change was determined by
subtracting weight at baseline from weight at 1 year, then
dividing by weight at baseline. We defined weight change
categorically as >2% gain, maintained weight (≤2% gain or
<2% loss), ≥2% to <5% loss, ≥5% to <10% loss, and ≥10%
loss. These categories were chosen to examine the recom-
mended weight loss target of 5–10% [28, 29] and compare it
against greater or lesser weight loss, while separating those
who gained weight from those who maintained their baseline
weight.
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Weight change, CVD events and all-cause mortality We used
Cox proportional hazards regression to estimate HRs for cat-
egory of weight change, 10 year incidence of CVD events and
10 year all-cause mortality. Due to the small numbers of CVD
events among participants who lost the most weight, we com-
bined the ≥5% to <10% loss and ≥10% loss categories.
The timescale was the number of days since diabetes diag-
nosis. Person-time at risk began 1 year after diabetes diagnosis
and ended at the time of the event, death or 31 December
2014. We assessed the proportional hazards assumption by
modelling an interaction term between the natural log of time
and each covariate, which indicated no departures from pro-
portional hazards. All models adjusted for confounders iden-
tified using a directed acyclic graph [30]: age at baseline (con-
tinuous), sex (female, male), trial group (intensive treatment,
routine care), baseline occupational SES (‘professional, man-
agerial and technical’, ‘skilled-manual and non-manual’ and
‘partly skilled or unskilled’), BMI at baseline (continuous,
coded as a quadratic term), cigarette-smoking status at 1 year
(current, former, never), and use of antihypertensive (yes, no),
glucose-lowering (yes, no) and lipid-lowering (yes, no) med-
ication at 1 year. Clustering of individuals within GPs was
accounted for using a robust cluster variance estimator.
To assess heterogeneity of associations by age, we modelled
an interaction term between weight change and age at diagno-
sis. As past research has shown negative impacts of weight loss
on mortality among older adults [31–33], we performed sepa-
rate analyses to estimate the associations of interest among
those aged ≥65 years at the time of diabetes diagnosis.Wewere
unable to stratify by age at diagnosis <65 years owing to the
small number of cases in this age group.
In a sensitivity analysis, we used multiple imputation by
chained equations [34] to estimate associations among the full
cohort including the 137 individuals with missing weight in-
formation. The imputation models included covariates for
weight change category; sex; occupational SES; baseline
BMI; smoking; treatment group; antihypertensive, glucose-
lowering and lipid-lowering medication use at 1 year; out-
come status; and the Nelson–Aalen estimate of cumulative
hazard. We generated 20 imputed datasets and used these to
estimate HRs in the full cohort. Separate imputation models
were fit where the outcome was all-cause mortality. We also
assessed the robustness of our results to changes in weight
after the first year in the study by adjusting for weight change
from year 1 to year 5. Additional sensitivity analyses excluded
individuals with a history of myocardial infarction or stroke
prior to diagnosis of diabetes (n = 77); separate analyses ex-
cluded revascularisation and amputations from the composite
CVD outcome (n = 37) in order to estimate HRs for a com-
posite of stroke, myocardial infarction or cardiovascular
death. To evaluate the association of weight change and
CVD occurring in the presence of the competing risk of
non-CVD mortality, we estimated subdistribution HRs [35].
Weight loss and CVD risk factors We used linear regression
models to estimate the associations between percentage
weight loss in the year following diabetes diagnosis and
CVD risk factors (HbA1c, systolic and diastolic BP, triacyl-
glycerols, total cholesterol and LDL-cholesterol) at 1 year and
5 years. Percentage weight change categories were defined as
above.
The adjustment set was the same as in the proportional
hazards models, except that each model was adjusted for rel-
evant medication use in the year the outcome was measured
(e.g. glucose-lowering agents for HbA1c, antihypertensive
medication for BP, and lipid-lowering medication for lipid
levels), rather than adjusting for each type of medication
use. Separate analyses were stratified by medication use at
1 year and 5 years to assess possible heterogeneity of the
associations. Sensitivity analyses were conducted: (1) using
multiple imputation by chained equations [34] to estimate the
associations of percentage weight change and the CVD risk
factors among the full cohort; [2] by adjusting for baseline
values of the risk factors.
Results
Of the 99 first incident CVD events, 36 were revascularisations,
24 were strokes, 21 were CVD deaths, 17 were myocardial
infarctions and one was an amputation. Of the 95 incident
deaths during the study period, 31 were related to CVD, 45 to
cancer and 19 to another cause. Mean follow-up time was
9.8 years.
Of the 725 study participants with non-missing weight in-
formation and no CVD event during the first year in the study,
62%weremale, 97%were white and themean age at diagnosis
of diabetes was 61 years. At baseline 34.8% had a professional
occupation, 23.0% had a skilled occupation and 42.3% had an
unskilled occupation. Mean weight change (SD) during the
study period was −3.6 kg (5.5 kg) at 1 year (Table 1) and
−4.1 kg (7.1 kg) at 5 years (not shown). Use of lipid-
lowering and glucose-lowering medication increased through-
out the study period (Table 1). As distributions of weight
changes and CVD risk factors were similar between men and
women (electronic supplementary material [ESM] Table 1), all
participants were analysed together. CVD risk factors largely
improved across the study period. Those who lost ≥5% body
weight had somewhat larger decreases in systolic BP at 1 year
and 5 years compared with the other groups (Table 2). After
stratifying by category of weight change in the first year in the
study, the mean weight at 5 years in the study was similar to the
mean weight at 1 year in the study (ESM Table 2).
Missing weight information at baseline or 1 year was asso-
ciated with SES and smoking: unskilled workers were more
likely to have missing weight compared with professional
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workers, and non-smokers were less likely to have missing
weight compared with current smokers (ESM Table 3).
Weight change, 10 year CVD events and all-cause
mortality
Losing ≥5% of body weight was associated with a lower haz-
ard of 10 year CVD events compared with maintaining weight
(HR 0.52 [95% CI 0.32, 0.86]). Associations between weight
gain and 10 year CVD incidence (HR 0.41 [95% CI 0.15,
1.11]) and all-cause mortality (HR 1.63 [95% CI 0.83, 3.19])
were less apparent. There were no associations between
weight loss and all-cause mortality (Table 3). The associations
were similar after adjusting for changes in weight between 1
and 5 years in the study (ESM Table 4). Results from analyses
with multiple imputation of missing information also showed
similar associations (ESM Table 5). Analyses excluding par-
ticipants with self-reported history of CVD were also similar
Table 1 Characteristics of individuals with type 2 diabetes at the time of diagnosis (baseline) and 1 year later by weight change category in the year
following diabetes diagnosis
Characteristic Full cohort (N = 725) Gained >2% weight
(n = 79)
Maintained weighta
(n = 222)
Lost ≥2% to <5%
weight (n = 183)
Lost ≥5% weight
(n = 241)
Baseline 1 year Baseline 1 year Baseline 1 year Baseline 1 year Baseline 1 year
Sex, n (%)
Female 279 (38.5) – 30 (38.0) – 71 (32.0) – 64 (35.0) – 114 (47.3) –
Male 446 (61.5) – 49 (62.0) – 151 (68.0) – 119 (65.0) – 127 (52.7) –
Missing 0 (0.0) – 0 (0.0) – 0 (0.0) – 0 (0.0) – 0 (0.0) –
Age, years 61.1 (7.1) – 60.8 (7.1) – 60.4 (7.5) – 61.0 (7.3) – 61.8 (6.4) –
Missing, n (%) 0 (0.0) – 0 (0.0) – 0 (0.0) – 0 (0.0) – 0 (0.0) –
BMI, kg/m2 33.4 (5.6) 32.2 (5.5) 32.3 (6.3) 33.8 (6.6) 32.8 (5.4) 32.8 (5.4) 33.4 (5.4) 32.4 (5.2) 34.2 (5.6) 30.9 (5.1)
Missing, n (%) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5) 1 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Weight, kg 94.6 (17.6) 91.0 (17.4) 91.5 (18.6) 95.8 (18.9) 94.3 (17.5) 94.0 (17.5) 95.0 (16.1) 91.9 (15.6) 95.7 (18.3) 86.1 (16.8)
Missing, n (%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Weight change from
baseline, kg
– −3.6 (5.5) – 4.3 (2.0) – −0.27 (1.0) – −3.1 (0.9) – −9.6 (4.7)
Smoking, n (%)
Current 120 (16.6) 106 (14.8) 12 (15.2) 9 (11.5) 34 (15.3) 27 (12.4) 31 (16.9) 32 (17.6) 43 (17.8) 38 (16.0)
Former 337 (46.5) 343 (48.0) 27 (34.2) 29 (37.2) 124 (55.9) 127 (58.3) 86 (47.0) 85 (46.7) 100 (41.5) 102 (43.0)
Never 268 (37.0) 266 (37.2) 40 (50.6) 40 (51.3) 64 (28.8) 64 (29.4) 66 (36.1) 65 (35.7) 98 (40.7) 97 (40.9)
Missing 0 (0.0) 10 (1.4) 0 (0.0) 1 (1.3) 0 (0.0) 4 (1.8) 0 (0.0) 1 (0.5) 0 (0.0) 4 (1.7)
Alcohol
Units/week 7.5 (10.8) 6.6 (9.8) 10.0 (13.6) 9.6 (13.5) 9.0 (11.8) 8.4 (11.1) 7.1 (10.6) 5.9 (8.6) 5.6 (8.3) 4.6 (7.3)
Missing, n (%) 11 (1.5) 17 (2.3) 1 (1.3) 2 (2.5) 4 (1.8) 5 (2.3) 3 (1.6) 5 (2.7) 3 (1.2) 5 (2.1)
Prescribed medication use, n (%)
Glucose-lowering
Yes 2 (0.3) 216 (30.6) 1 (1.3) 31 (40.8) 0 (0.0) 63 (29.4) 1 (0.5) 60 (33.7) 0 (0.0) 62 (26.2)
No 723 (99.7) 489 (69.4) 78 (98.7) 45 (59.2) 222 (100.0) 151 (70.6) 182 (99.5) 118 (66.3) 241 (100.0) 175 (73.8)
Missing 0 (0.0) 20 (2.8) 0 (0.0) 3 (3.8) 0 (0.0) 8 (3.6) 0 (0.0) 5 (2.7) 0 (0.0) 4 (1.7)
Antihypertensive
Yes 414 (57.1) 485 (68.8) 51 (64.6) 56 (73.7) 121 (54.5) 136 (63.6) 111 (60.7) 130 (73.0) 131 (54.4) 163 (68.8)
No 311 (42.9) 220 (31.2) 28 (35.4) 20 (26.3) 101 (45.5) 78 (36.4) 72 (39.3) 48 (27.0) 110 (45.6) 74 (31.2)
Missing 0 (0.0) 20 (2.8) 0 (0.0) 3 (3.8) 0 (0.0) 8 (3.6) 0 (0.0) 5 (2.7) 0 (0.0) 4 (1.7)
Lipid-lowering
Yes 173 (23.9) 462 (65.5) 18 (22.8) 51 (67.1) 58 (26.1) 123 (57.5) 48 (26.2) 128 (71.9) 49 (20.3) 160 (67.5)
No 552 (76.1) 243 (34.5) 61 (77.2) 25 (32.9) 164 (73.9) 91 (42.5) 135 (73.8) 50 (28.1) 192 (79.7) 77 (32.5)
Missing 0 (0.0) 20 (2.8) 0 (0.0) 3 (3.8) 0 (0.0) 8 (3.6) 0 (0.0) 5 (2.7) 0 (0.0) 4 (1.7)
Data are from a prospective cohort analysis of participants recruited in ADDITION–Cambridge between 2002 and 2014
Data are presented as mean (SD) except where otherwise stated
a Defined as ≤2% gain or <2% loss
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(ESM Table 6), as were analyses excluding revascularisations
and amputations (ESM Table 7). In the subdistribution haz-
ards analysis, the associations with CVD were unchanged
(ESM Table 8).
There was no evidence of an interaction between age at
diabetes diagnosis and weight change (p > 0.05). Among those
aged ≥65 years at the time of diabetes diagnosis, losing ≥5%
body weight was associated with a lower hazard of CVD com-
pared with maintaining weight (HR 0.39 [95% CI 0.16, 0.94])
but was not associated with all-cause mortality. Weight gain
was suggestively associated with a lower hazard of CVD (HR
0.66 [95%CI 0.20, 2.15]) and a higher hazard of mortality (HR
2.07 [95% CI 0.81, 5.30]) among those aged ≥65 years, albeit
the results were not statistically significant (Table 3).
Weight change and CVD risk factors
Compared with participants who maintained weight, those
who lost ≥5% body weight had lower HbA1c, diastolic BP
and triacylglycerols at 1 year. At 5 years, these improvements
were only apparent among those who had lost ≥10% weight.
Total cholesterol was improved at 1 year and 5 years among
those who lost ≥10% weight. Those who gained weight had
suggestive improvements in total and LDL-cholesterol at
1 year but not at 5 years (Table 4). After multiple imputation
of missing weight information, the observed associations were
slightly stronger (ESM Table 9). After adjusting for baseline
risk factor values, the results were similar (ESM Table 10).
After stratifying by relevant medication use at 1 year, par-
ticipants who lost ≥5% body weight had lower triacylglycer-
ols, irrespective of lipid-lowering medication use (ESM
Table 11).
Discussion
In this study of 725 individuals with screen-detected type 2
diabetes, loss of ≥5% body weight was associated with a 48%
lower 10 year hazard of CVD incidence vs maintaining
weight, after adjustment for age, sex, baseline BMI, SES,
smoking, medication use and trial arm. Associations were
independent of changes in weight between 1 and 5 years in
the study and were consistent among adults aged ≥65 years at
the time of diabetes diagnosis. Loss of ≥10% bodyweight was
associated with improvements in HbA1c, total cholesterol and
triacylglycerols at 5 years following diagnosis, which might
have contributed to the observed association of weight loss
and CVD events. There was no apparent association between
weight loss and all-cause mortality. Weight gain was also non-
statistically significantly associated with lower hazard of
CVD, but possibly higher hazard of all-cause mortality.
While extreme weight loss among people with type 2 dia-
betes achieved through bariatric surgery has been shown to
reduce the risk of CVD [36], studies of weight loss in non-
surgery populations have shown inconsistent associations
with mortality and incidence of CVD [9, 37]. A Scottish
Table 3 HRs for the associations
of change in weight in the year
following diabetes diagnosis and
10 year incidence of CVD and
mortality
Sample 10 year CVD incidence 10 year all-cause mortality
Cases/total, n HR (95% CI)a Cases/total, n HR (95% CI)a
Full cohort (N = 725)
Weight change
Gained >2% 6/75 0.41 (0.15, 1.11) 13/75 1.63 (0.83, 3.19)
Maintainedb 40/210 1.00 23/210 1.00
Lost ≥2% to <5% 26/173 0.79 (0.43, 1.46) 22/172 1.08 (0.60, 1.93)
Lost ≥5% 22/229 0.52 (0.32, 0.86) 30/228 1.12 (0.52, 2.37)
Age ≥65 years (n = 278)
Weight change
Gained >2% 4/26 0.66 (0.20, 2.15) 9/26 2.07 (0.81, 5.30)
Maintainedb 20/78 1.00 14/78 1.00
Lost ≥2% to <5% 16/72 0.87 (0.41, 1.87) 18/72 1.32 (0.63, 2.78)
Lost ≥5% 8/84 0.39 (0.16, 0.94) 15/84 1.03 (0.37, 2.81)
Data are from a prospective cohort analysis of participants recruited in ADDITION–Cambridge between 2002
and 2014
Sample sizes comprise only cases where data are available for weight change, age, sex, baseline SES, baseline
BMI, smoking at 1 year and use of antihypertensive, lipid- or glucose-lowering medication at 1 year
a HRs are adjusted for age, sex, baseline SES, baseline BMI, smoking at 1 year, use of antihypertensive, lipid- or
glucose-lowering medication at 1 year, and trial arm
bDefined as ≤2% gain or <2% loss at 1 year
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observational study of weight change within 2 years of diabe-
tes diagnosis and 5 year incidence of CVD showed no benefits
of weight loss [11]. However, the magnitude of weight lost in
this cohort was relatively low (mean weight change −0.7% ±
6.7%) compared with the −3.7% ± 5.7% mean weight change
in the current study. The ROSE study also showed no associ-
ation between reductions in BMI in the 18 months following
diabetes diagnosis and 5 year CVD risk [12]. While the
Table 4 β coefficients and 95%
CIs derived from multivariable
linear regression models of the
associations of weight change in
the year following diabetes diag-
nosis and cardiovascular risk fac-
tors measured at 1 and 5 years
after diagnosis
Risk factor Outcomes measured at 1 year Outcomes measured at 5 years
n β (95% CI)a n β (95% CI)a
HbA1c (mmol/mol)
Gained >2% 74 2.33 (−0.26, 4.92) 71 −0.36 (−3.45, 2.73)
Maintainedb 206 0 192 0
Lost ≥2% to <5% 172 −1.95 (−4.00, 0.11) 166 −1.25 (−3.67, 1.16)
Lost ≥5% to <10% 129 −4.91 (−6.54, −3.27) 124 −1.10 (−3.95, 1.74)
Lost ≥10% 96 −6.92 (−9.14, −4.71) 90 −3.72 (−6.28, −1.16)
Systolic BP, mmHg
Gained >2% 75 0.93 (−5.22, 7.09) 71 −0.96 (−5.39, 3.47)
Maintainedb 210 0 196 0
Lost ≥2% to <5% 172 −3.52 (−6.59, −0.45) 168 −1.47 (−4.79, 1.85)
Lost ≥5% to <10% 131 −2.65 (−7.04, 1.74) 125 1.67 (−2.80, 6.14)
Lost ≥10% 98 −4.73 (−9.17, −0.29) 92 −2.30 (−6.44, 1.83)
Diastolic BP, mmHg
Gained >2% 75 0.11 (−2.25, 2.47) 71 −0.45 (−3.77, 2.87)
Maintainedb 210 0 196 0
Lost ≥2% to <5% 172 −1.27 (−2.90, 0.36) 168 −0.56 (−2.36, 1.24)
Lost ≥5% to <10% 131 −2.37 (−4.03, −0.71) 125 −0.44 (−2.32, 1.44)
Lost ≥10% 98 −3.54 (−5.86, −1.23) 92 −2.41 (−4.76, −0.07)
Total cholesterol, mmol/l
Gained >2% 75 −0.26 (−0.51, −0.01) 71 −0.11 (−0.29, 0.06)
Maintainedb 209 0 194 0
Lost ≥2% to <5% 173 −0.09 (−0.26, 0.09) 165 −0.17 (−0.32, −0.02)
Lost ≥5% to <10% 130 −0.24 (−0.46, −0.02) 123 −0.15 (−0.32, 0.02)
Lost ≥10% 97 −0.32 (−0.49, −0.15) 92 −0.21 (−0.38, −0.04)
LDL-cholesterol, mmol/l
Gained >2% 75 −0.25 (−0.46, −0.04) 68 −0.04 (−0.23, 0.15)
Maintainedb 195 0 182 0
Lost ≥2% to <5% 168 −0.06 (−0.20, 0.08) 155 −0.19 (−0.33, −0.04)
Lost ≥5% to <10% 128 −0.12 (−0.25, 0.00) 117 −0.12 (−0.26, 0.02)
Lost ≥10% 96 −0.12 (−0.25, 0.00) 89 −0.15 (−0.30, 0.01)
Triacylglycerolsc, mmol/l
Gained >2% 75 −0.11 (−0.25, 0.04) 70 −0.17 (−0.31, −0.03)
Maintainedb 209 0 192 0
Lost ≥2% to <5% 173 −0.10 (−0.21, 0.00) 164 −0.07 (−0.19, 0.04)
Lost ≥5% to <10% 130 −0.21 (−0.33, −0.10) 121 −0.09 (−0.23, 0.05)
Lost ≥10% 97 −0.46 (−0.59, −0.32) 90 −0.30 (−0.42, −0.17)
Data are from a prospective cohort analysis of N = 725 participants recruited in ADDITION–Cambridge between
2002 and 2014
aβ coefficient values are from linear regression models adjusted for age, sex, SES, baseline BMI, smoking at
1 year, relevant medication use at 1 or 5 years, and trial arm. Coefficients represent the change in the specified
outcome of interest by category of weight change, with all other variables in the model held constant
b Defined as ≤2% gain or <2% loss at 1 year
c Calculated from loge of triacylglycerols in mmol/l
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magnitude of weight loss in the ROSE study was comparable
to that in ADDITION–Cambridge (mean BMI decrease
among those who lost weight was 2.5 kg/m2, or 7.6% of base-
line BMI), those who had lost weight had a higher BMI across
the study period compared with those with unchanged weight.
This was not the case in our study, where those who lost the
most weight had a lower BMI across the study period com-
pared with those who had maintained or gained weight (ESM
Table 2). Additionally, the ROSE study had a relatively short
follow-up (median 5 years) and did not control for antihyper-
tensive medication use or smoking [38]. Furthermore, unin-
tentional weight loss due to underlying disease might have
masked any protective impact of weight loss on CVD.
One year weight loss of ≥10% body weight was associated
with a 21% lower 10 year hazard of CVD in the Look
AHEAD trial. We observed similarly strong, protective asso-
ciations with ≥5%weight loss. This may be due to the fact that
we targeted weight loss following diagnosis of diabetes via
screening, whereas in Look AHEADweight loss occurred, on
average, 7 years after clinical diabetes diagnosis. Weight loss
in the early stages of diabetes may result in a legacy effect to
reduce long-term incidence of CVD, as was observed with
short-term intensive glucose control in the UKPDS [16].
Weight loss was associated with improvements in HbA1c, lip-
id levels and BP at 1 year in the study. Few of these associa-
tions persisted at 5 years; however, it is possible that improve-
ment in risk factors early on contributed to the observed lower
incidence of CVD among those who lost the most weight.
Furthermore, changes in BP, blood lipids and blood glucose
only partially explain the mechanisms by which healthy be-
haviours lower CVD risk [39]. Increases in physical activity
among those who lost weight might have reduced the risk of
CVD through inflammatory mechanisms independently of the
risk factors measured in our study.
Unintentional weight loss due to sarcopenia or cancer in-
creases the short-term risk of mortality [40] and may be a
source of unmeasured confounding in our study. To address
potential confounding, we excluded deaths occurring in the
year following the assessment of weight change, to reduce the
likelihood that weight loss in our study was caused by disease.
The protective association between weight loss and CVD risk
observed in this study remained evident after restriction to
participants aged ≥65 years at the time of diagnosis. We can-
not definitively determine that weight loss in this study was
intentional and because of healthy lifestyle changes rather
than age-related or cancer-related wasting; however, the fact
that we excluded deaths occurring within 1 year following the
initial weight loss, and that our results were robust among
older participants, supports our interpretation that weight loss
was unlikely to be the result of underlying disease.
Unmeasured socioeconomic or baseline health differences
may also modify associations with weight loss; it is possible
that weight loss may be achievable and helpful for some
people but unachievable or unhealthy for others. We cannot
rule out the possibility that those who lost weight might have
been more willing and able to healthily lose weight compared
with those who did not lose weight, or the potential for other
unmeasured confounding. Therefore, our results may only be
applicable to people who are willing and able to lose weight.
Compared with maintaining weight, weight gain >2% had
a suggestive protective association with CVD and a sugges-
tive adverse association with mortality. These results were not
statistically significant and should be interpreted with caution,
as only 75 study participants gained weight. Considering the
existing literature, there is no substantiating evidence that
weight gain is protective against CVD among people with
type 2 diabetes. In the ROSE study, weight gain was associ-
ated with a higher hazard of 5 year all-cause mortality com-
pared with maintaining weight [12]. Smoking cessation is
associated with reduced CVD risk and weight gain; however,
it is unlikely that it would have introduced confounding, as we
controlled for cigarette smoking and only 17 study partici-
pants had given up smoking during the 1 year period when
weight was measured. There may be heterogeneity in the as-
sociations of weight gain and CVD by baseline BMI; we
adjusted for baseline BMI but we did not have a sufficient
sample size to perform stratified analyses. Among those who
gained weight, we might have under-ascertained CVD inci-
dence because of the competing risk of mortality; however, as
we censored participants at the time of death, person-time
following a competing event was not included in the risk set.
In a sensitivity analysis we estimated subdistribution HRs [35]
to incorporate person-time of individuals who experienced a
competing event, and the results were unchanged. Regardless,
the observed associations of weight gain and CVD had poor
precision and may be due to chance.
The ADDITION–Cambridge cohort was predominantly
white, which limits generalisability to other populations. The
majority of participants were overweight or obese at diagno-
sis, and although we adjusted for baseline BMI, the results
would not necessarily apply to people with a normal weight
or those who are underweight. We had approximately 15%
missing information on weight at baseline or 1 year follow-
up. Multiple imputation of missing information on weight
showed generally similar associations, indicating results were
robust to missing data under the assumption that missingness
occurred at random, conditional on the covariates included in
the imputation model. The relationship between weight
change and CVD risk might have been confounded by health
differences between those who maintained, gained or lost
weight and differences in medication use across the study
period. However, we adjusted for CVD risk factors including
smoking, BMI, SES and cardio-protective medication use.
While we adjusted for glucose-lowering medication, we were
not able to separately account for metformin and sulfonyl-
ureas, as only 28 study participants were using sulfonylureas
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at 1 year. Sulfonylurea use was most common among partic-
ipants who gained weight. Metformin use comprised the ma-
jority of glucose-lowering drug use in this cohort, reducing
our concerns of bias related to differential effects of glucose-
lowering drugs on weight and CVD [41]. Exclusion of partic-
ipants who reported sulfonylurea use at 1 year did not change
any associations (not shown). We assessed a number of risk
factors at two time points, which might have increased the
probability of a type I error. However, other studies have re-
ported similar associations between weight loss and cardio-
vascular risk factors [42].
Of all high-risk individuals who were invited to participate
in screening, 74% attended screening and all 867 individuals
diagnosed with diabetes consented to enrol in the study,
resulting in a study population which affords generalisability
to the broader primary care population of eastern England.
Due to the screening-based nature of this study, we were able
to capture weight change during the period immediately fol-
lowing diabetes diagnosis, to assess whether moderate,
achievable weight loss during this period can reduce long-
term CVD risk. Adjustment for confounders including ciga-
rette smoking and cardio-protective medication use improves
the internal validity of our study relative to other studies of
weight loss and CVD which did not adjust for these [11, 12].
Loss of ≥5% body weight during the year following diabetes
diagnosis was associated with a lower hazard of CVD events at
10 years but was not associated with all-causemortality.Weight
loss ≥5% was also associated with improvements in HbA1c,
diastolic BP and lipids at 1 year, while weight loss ≥10% was
associated with improvements at 5 years. There is growing
recognition of the impact of weight loss on diabetes remission,
and our research supports the hypothesis that moderate weight
loss in the year following diabetes diagnosis may yield substan-
tial long-term CVD reduction and may be an achievable target
for individuals with a new diagnosis of type 2 diabetes.
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